Research Article
BibTex RIS Cite
Year 2020, Volume: 10 Issue: 4, 443 - 447, 30.12.2020
https://doi.org/10.33808/clinexphealthsci.605644

Abstract

References

  • Slawsky, M.T., Colucci, W.S., Gottlieb, S.S., Greenberg, B.H., Haeusslein, E., Hare, J., Hutchins, S., Leier, C.V., LeJemtel, T.H., Loh, E. and Nicklas, J., 2000. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation, 102(18), pp.2222-2227.

Usage and Results of Levosimendan in Ischemic Mitral Valve Surgery

Year 2020, Volume: 10 Issue: 4, 443 - 447, 30.12.2020
https://doi.org/10.33808/clinexphealthsci.605644

Abstract

Objective: Large number of comprehensive studies has been carried out on levosimendan. There are many studies on its use, especially in cardiac dysfunction, ischemic cardiac surgery, and heart transplantation surgery. But, there are limited number of studies regarding its use in mitral valve interventions and ischemic mitral dysfunction combined with coronary artery by-pass surgery (CABG). We aimed to investigate the efficacy of levosimendan usage on patients undergone combined coronary artery by-pass grafting and mitral valve surgery because of ischemic mitral dysfunction.
Methods: Subsequent patients, who have undergone concurrent CABG and mitral valve repair surgery by a single surgery team, were retrospectively examined. 36 patients were divided into 2 groups; Group 1 (levosimendan therapy group, n=15) and Group 2 (n=21).
Results: There was no statistically significant difference between the groups in terms of preoperative characteristics, echocardiographic data of the patients and preoperative medication. Inotrope therapy was required for 12 patients in Group 1, which was statistically higher than Group 2 (n=5, p=0.001). Moreover, IABP following LCOS utilized six and two patients in group 1 and 2 with a statistically significant difference (p=0.03), espectively.
Conclusion: We recommend using levosimendan on selected patients for its several beneficial effects. However, we do not satisfied with the treatment because the pathology of all patients was not related to ischemia, more to the alteration of ventricle anatomy with deterioration of diameters.

References

  • Slawsky, M.T., Colucci, W.S., Gottlieb, S.S., Greenberg, B.H., Haeusslein, E., Hare, J., Hutchins, S., Leier, C.V., LeJemtel, T.H., Loh, E. and Nicklas, J., 2000. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation, 102(18), pp.2222-2227.
There are 1 citations in total.

Details

Primary Language English
Subjects Health Care Administration
Journal Section Articles
Authors

Murat B. Rabus This is me 0000-0002-4952-8637

Mehmet Dedemoglu This is me 0000-0002-5532-4307

Ozge Altas This is me 0000-0002-3610-8465

Davut Cekmecelioglu This is me 0000-0003-1946-326X

Mehmet Aksut This is me 0000-0002-0280-7890

Rahmi Zeybek This is me 0000-0003-1639-9207

Publication Date December 30, 2020
Submission Date January 10, 2019
Published in Issue Year 2020 Volume: 10 Issue: 4

Cite

APA Rabus, M. B., Dedemoglu, M., Altas, O., Cekmecelioglu, D., et al. (2020). Usage and Results of Levosimendan in Ischemic Mitral Valve Surgery. Clinical and Experimental Health Sciences, 10(4), 443-447. https://doi.org/10.33808/clinexphealthsci.605644
AMA Rabus MB, Dedemoglu M, Altas O, Cekmecelioglu D, Aksut M, Zeybek R. Usage and Results of Levosimendan in Ischemic Mitral Valve Surgery. Clinical and Experimental Health Sciences. December 2020;10(4):443-447. doi:10.33808/clinexphealthsci.605644
Chicago Rabus, Murat B., Mehmet Dedemoglu, Ozge Altas, Davut Cekmecelioglu, Mehmet Aksut, and Rahmi Zeybek. “Usage and Results of Levosimendan in Ischemic Mitral Valve Surgery”. Clinical and Experimental Health Sciences 10, no. 4 (December 2020): 443-47. https://doi.org/10.33808/clinexphealthsci.605644.
EndNote Rabus MB, Dedemoglu M, Altas O, Cekmecelioglu D, Aksut M, Zeybek R (December 1, 2020) Usage and Results of Levosimendan in Ischemic Mitral Valve Surgery. Clinical and Experimental Health Sciences 10 4 443–447.
IEEE M. B. Rabus, M. Dedemoglu, O. Altas, D. Cekmecelioglu, M. Aksut, and R. Zeybek, “Usage and Results of Levosimendan in Ischemic Mitral Valve Surgery”, Clinical and Experimental Health Sciences, vol. 10, no. 4, pp. 443–447, 2020, doi: 10.33808/clinexphealthsci.605644.
ISNAD Rabus, Murat B. et al. “Usage and Results of Levosimendan in Ischemic Mitral Valve Surgery”. Clinical and Experimental Health Sciences 10/4 (December 2020), 443-447. https://doi.org/10.33808/clinexphealthsci.605644.
JAMA Rabus MB, Dedemoglu M, Altas O, Cekmecelioglu D, Aksut M, Zeybek R. Usage and Results of Levosimendan in Ischemic Mitral Valve Surgery. Clinical and Experimental Health Sciences. 2020;10:443–447.
MLA Rabus, Murat B. et al. “Usage and Results of Levosimendan in Ischemic Mitral Valve Surgery”. Clinical and Experimental Health Sciences, vol. 10, no. 4, 2020, pp. 443-7, doi:10.33808/clinexphealthsci.605644.
Vancouver Rabus MB, Dedemoglu M, Altas O, Cekmecelioglu D, Aksut M, Zeybek R. Usage and Results of Levosimendan in Ischemic Mitral Valve Surgery. Clinical and Experimental Health Sciences. 2020;10(4):443-7.

14639   14640